COX-2 gene doubles risk of ovarian cancer:
This article was originally published in Clinica
Executive Summary
Variations in the COX-2 gene can double or even treble a woman's risk of ovarian cancer. In a 727-patient study, Portuguese researchers found that a specific allele of the gene doubled the risk of the disease, and trebled the likelihood in women under 53. Since other COX-2 influenced diseases can be treated with non-steroidal anti-inflammatory drugs (NSAIDS), the finding raises the possibility of a theranostic test for the disease, said the researchers, based at the Portuguese Institute of Oncology in Porto. It is thought that NSAIDS, such as ibuprofen and aspirin, could be used to help prevent ovarian cancer in those who test positive. The results were presented at the conference of the European CanCer Organisation (ECCO) in Barcelona, Spain, from 23-27 September.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.